Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Recommendation of “Hold” from Brokerages

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA) have been assigned a consensus recommendation of “Hold” from the eleven ratings firms that are covering the company, MarketBeat reports. Three research analysts have rated the stock with a sell rating, two have assigned a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $8.1250.

NMRA has been the subject of a number of recent analyst reports. Leerink Partners initiated coverage on Neumora Therapeutics in a report on Monday, January 12th. They issued an “outperform” rating and a $8.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Neumora Therapeutics in a research note on Thursday, January 22nd. Stifel Nicolaus lifted their price objective on shares of Neumora Therapeutics from $2.00 to $3.00 and gave the company a “hold” rating in a research note on Monday, November 17th. Needham & Company LLC upped their price objective on shares of Neumora Therapeutics from $6.00 to $8.00 and gave the stock a “buy” rating in a report on Tuesday, October 28th. Finally, Guggenheim raised shares of Neumora Therapeutics from a “neutral” rating to a “buy” rating and set a $14.00 target price on the stock in a research note on Monday, October 27th.

Neumora Therapeutics Trading Down 3.0%

Shares of NASDAQ:NMRA opened at $1.96 on Friday. The company has a quick ratio of 6.85, a current ratio of 6.85 and a debt-to-equity ratio of 0.15. The company’s 50-day moving average price is $2.00 and its 200 day moving average price is $1.99. The company has a market cap of $327.50 million, a PE ratio of -1.33 and a beta of 3.20. Neumora Therapeutics has a fifty-two week low of $0.61 and a fifty-two week high of $3.25.

Neumora Therapeutics (NASDAQ:NMRA) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.01). Sell-side analysts anticipate that Neumora Therapeutics will post -1.61 earnings per share for the current year.

Insider Activity

In related news, insider Daljit Singh Aurora sold 114,703 shares of the firm’s stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $2.68, for a total transaction of $307,404.04. The transaction was disclosed in a document filed with the SEC, which is available at this link. 26.80% of the stock is owned by company insiders.

Hedge Funds Weigh In On Neumora Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Jacobs Levy Equity Management Inc. acquired a new position in shares of Neumora Therapeutics during the 3rd quarter valued at $1,512,000. Millennium Management LLC boosted its stake in Neumora Therapeutics by 63.1% during the third quarter. Millennium Management LLC now owns 2,008,248 shares of the company’s stock valued at $3,655,000 after buying an additional 776,856 shares in the last quarter. AQR Capital Management LLC acquired a new position in Neumora Therapeutics during the first quarter worth about $463,000. AlphaCore Capital LLC bought a new stake in Neumora Therapeutics in the second quarter worth about $248,000. Finally, Marshall Wace LLP acquired a new stake in Neumora Therapeutics in the 2nd quarter valued at about $183,000. 47.65% of the stock is owned by institutional investors.

Neumora Therapeutics Company Profile

Neumora Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing precision therapies for disorders of the central nervous system. The company applies an integrated approach that combines advanced biological insights, single-cell genomics and machine learning to accelerate the discovery and development of novel treatments for neurological and psychiatric diseases.

Neumora’s product pipeline spans small molecules, biologics and gene-based modalities targeting areas of high unmet need such as neurodegenerative conditions, mood and anxiety disorders, neuropathic pain and movement disorders.